Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Cash: 2012-2024

Historic Change in Cash for Akebia Therapeutics (AKBA) over the last 13 years, with Dec 2024 value amounting to $9.0 million.

  • Akebia Therapeutics' Change in Cash rose 632.35% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.4 million, marking a year-over-year increase of 1160.93%. This contributed to the annual value of $9.0 million for FY2024, which is 118.46% up from last year.
  • As of FY2024, Akebia Therapeutics' Change in Cash stood at $9.0 million, which was up 118.46% from -$48.6 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Change in Cash ranged from a high of $81.3 million in FY2020 and a low of -$79.3 million during FY2021.
  • Its 3-year average for Change in Cash is -$32.8 million, with a median of -$48.6 million in 2023.
  • In the last 5 years, Akebia Therapeutics' Change in Cash slumped by 197.50% in 2021 and then spiked by 118.46% in 2024.
  • Yearly analysis of 5 years shows Akebia Therapeutics' Change in Cash stood at $81.3 million in 2020, then slumped by 197.50% to -$79.3 million in 2021, then climbed by 26.01% to -$58.7 million in 2022, then climbed by 17.18% to -$48.6 million in 2023, then soared by 118.46% to $9.0 million in 2024.